China’s Sinovac COVID-19 vaccine is 67% effective in preventing symptomatic infection – Report from Chile

Shared vials of the Sinovac COVID-19 vaccine are seen as the Thai resort island of Phuket, which is in a hurry to vaccinate the population amid the coronavirus disease (COVID-19), and before the end of July 1 of strict quarantine for overseas visitors. tourism revenue back in Phuket, Thailand, April 1, 2021. REUTERS / Jorge Silva

Sinovac’s COVID-19 vaccine CoronaVac was 67% effective in preventing symptomatic infection in the first actual study of the Chinese shot, the Chilean government said on Friday.

The vaccination was 85% effective in preventing hospitalizations and 80% effective in preventing deaths, the government said in a report compiled by the Chilean Ministry of Health.

The release of the data makes Chile one of a handful of countries, including the UK and Israel, that have used vaccination campaigns to gather insights into how effective vaccines are outside of controlled clinical trials and when they face unpredictable variables in societies. Com.

Israel’s actual study on the effectiveness of Pfizer’s (PFE.N) vaccine looked at the results among 1.2 million people, a mix of those who got the chance and those who did not get the chance.

The Chile study examined the effectiveness of CoronaVac among 10.5 million people and looked again at people who have been vaccinated and those who have not been vaccinated. Vaccines were administered about 28 days apart in Chile.

The data compares favorably with previous data released on the efficacy of CoronaVac in clinical trials.

In January, a Brazilian experiment said the overall effectiveness of the drug in preventing symptomatic infection was 50.4%. A later study, published this month, found that the efficacy against symptomatic COVID-19 was 50.7%, the efficacy against cases requiring medical treatment was 83.7%, and the efficacy against moderate and severe cases. 100%.

Indonesia has given the vaccine approval for emergencies based on interim data showing that it is 65% effective.

In a Turkish trial, CoronaVac had an efficacy to prevent symptomatic infection of 83.5%, and 100% to prevent serious illness and hospitalization.

The Chilean study looked at the impact of vaccination among people in the public health system between February 2 and April 1, and was adjusted for age, gender, comorbidities, income level, and nationality.

The authors stressed that its results, for example a lower protection against death than in clinical trials, should be considered against the background of a severe second wave of the pandemic.

It compares people who have not been vaccinated, individuals 14 days or longer after receiving one dose and more than 14 days after receiving a second dose.

The results showed that people who were partially vaccinated, those with only one shot, were much more vulnerable to contracting COVID-19.

Our standards: the principles of the Thomson Reuters Trust.

.Source